If you're between the ages of 28 and 43, then get ready to go down memory lane because you're about to be hit with a strong ...

GSK’s Trelegy, a treatment for chronic obstructive pulmonary disease (COPD), aimed to address a gap in the market with its ...

Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time ...

Here’s a map of single-copy locations. Sign up for our daily newsletter here Two weeks ago, on one night alone, I saw five ...

MSD’s PD-1 inhibitor Keytruda has been approved by the FDA ... The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy.

Merck (NYSE:MRK) announced Tuesday that its Phase 3 KEYNOTE-689, designed to evaluate its anti-PD-1 therapy Keytruda as a ...

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

The last commercial actor you spotted might be destined for the A-list one day. Your favorite movie and TV star had to start somewhere and, sometimes, that somewhere is appearing in commercials.

In MSI-H or dMMR endometrial cancer, Keytruda achieved an objective response rate (ORR) of 46%, including 12% complete responses and 33% partial responses, after a median of 16 months' follow-up.

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...

Investors in Merck don't seem pleased with a competitor cancer-treatment candidate outperforming Keytruda. Summit Therapeutics says its monotherapy ivonescimab outperformed pembrolizumab ...